title: Preparing for microbicide introduction, rollout, and sustained access.
abstract: Two topical vaginal microbicide candidates for HIV prevention are at an advanced stage of clinical testing, with efficacy results from three clinical trials expected within the next 2 years. Therefore, preparations for introducing and ensuring access to these products in the event that they are proven safe and effective now require increased attention. Microbicides are expected to fill an important global public health need for HIV prevention options for women. They have been developed almost exclusively with public and private funding through academic and nongovernmental institutions and minimal involvement of commercial pharmaceutical partners. Efficient and rapid introduction of a new public health technology requires a broad range of expertise and collaborations, some of which are new to the microbicide field as products are at last completing late-stage pivotal licensure studies. Strong leadership, political commitment, and considerable financial investments will be required to ensure successful distribution as well as uptake and continued access to this new product class. This paper highlights work conducted since 2000 by scientists, advocates, and public health officials to prepare for microbicide introduction, and discusses some of the needed actions to ensure that products will become readily accessible to the women who need them.
authors.affiliation: International Partnership for Microbicides, Silver Spring, MD, 20910, USA, cwoodsong@ipmglobal.org.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Woodsong
authors.forename: Elizabeth
authors.initials: E
authors.lastname: McGrory
authors.forename: Tim
authors.initials: T
authors.lastname: Farley
mesh_terms: D019380:Anti-HIV Agents / Q000191:economics* / Q000494:pharmacology* / Q000600:supply & distribution; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics / Q000821:virology; D006801:Humans
chemical_list: D019380:Anti-HIV Agents